Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
November 6, 2025
-
REGULATORY Japan Launches Growth Strategy HQ, Sets Drug Discovery as Priority Field
November 5, 2025
-
BUSINESS Fuji, J&J Reach Agreement on Simponi Biosimilar for 2026 Debut
November 5, 2025
-
BUSINESS Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
November 4, 2025
-
BUSINESS Daiichi Sankyo’s Profit Down on HER3-DXd Delay, One-Off CMO Costs
November 4, 2025
-
BUSINESS Pfizer Resumes Supply of Smoking Cessation Pill Champix after 4 Years
October 31, 2025
-
BUSINESS Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
-
REGULATORY LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
October 31, 2025
-
REGULATORY Shionogi/Sage’s Zurzuvae Clears MHLW Panel, Label Wording on Combo Use under Review
October 31, 2025
-
REGULATORY Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
October 30, 2025
-
REGULATORY Data Error Delayed Japan Review of Subcutaneous Rybrevant; Approval Still Expected This Year
October 30, 2025
-
REGULATORY Public-Private WG’s Discussion Summary Focuses on Drug Pricing, Raises MFN Risk
October 29, 2025
-
BUSINESS NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
-
BUSINESS Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
-
BUSINESS Novo to End Sales of Victoza in Japan, Fourth GLP-1 to Exit Market
October 28, 2025
-
BUSINESS First Oral Small-Molecule GLP-1 Nears Filing; Broad Use Expected in Diabetes
October 27, 2025
-
BUSINESS Chugai Acquires Renalys Pharma, Bags IgAN Drug
October 27, 2025
-
BUSINESS Celltrion Files Biosimilar without Japanese Clinical Data, More Firms Might Follow
October 24, 2025
-
BUSINESS Earnings Season Kicks Off, Off-Year Revision Impact in Spotlight
October 24, 2025
-
BUSINESS And Pharma Group Subsidiaries Team Up for First Joint Promotion
October 23, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…